Repligen Completes Expansion of U.S. Facility
News Feb 12, 2015
Repligen Corporation has announced that it has completed an 11,000 square foot expansion of its U.S. manufacturing facility. The expansion includes a dedicated space for the production and assembly of Repligen's Alternating Tangential Flow System (“the ATF System”), the most recent addition to the Company’s upstream bioprocessing product portfolio.
The ATF System is a market-leading product line used to significantly increase cell density and product yield during the fermentation step of the biologic drug manufacturing process. The expansion includes areas for ATF System assembly, quality control and inventory, as well as cleanroom suites for the production of single-use ATF Systems in an ISO 7 environment that meets the high standards of Repligen’s biopharmaceutical customers.
"This expansion satisfies our goal to rapidly transfer ATF System operations, which we acquired from Refine Technology of Pine Brook, NJ in June 2014, to our Waltham facility. This new space is designed to meet the highest standards of quality and service that our customers expect from Repligen, and will improve lead times for product delivery,” said Walter C. Herlihy, Ph.D., retiring President and CEO of Repligen.
Tony J. Hunt, COO and named next CEO of Repligen added, “We are immediately addressing customer demand for the current stainless steel ATF System through our new manufacturing facility in Waltham and our expanded technical, service and applications support team, while continuing to execute on the development of a single-use version of the ATF System.”
The facility upgrade also expands on areas dedicated to cell culture research and development as well as manufacturing and support of the Company’s ELISA test kits and its OPUS® line of pre-packed chromatography columns.
An additional 7,500 square feet is reserved for future expansion of the Waltham facility, allowing the Company to remain flexible and responsive to the needs of its biopharmaceutical customers and life sciences partners.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE